The University of Houston Health Center, University of Houston, Texas, USA.
Am J Clin Dermatol. 2011 Feb 1;12(1):63-7. doi: 10.2165/11531920-000000000-00000.
Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of the eyelashes induced by these agents has predominantly been observed in oncology patients with either colorectal or lung cancer. It is most frequently associated with cetuximab and erlotinib; however, it has also been described in individuals treated with gefitinib or panitumumab. We describe cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal carcinoma. We review the clinical presentation, adverse effects, and management of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a drug-limiting adverse effect and some patients consider the change to be cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate local symptoms. The eyelashes often return to their original length at variable time periods after EGFR inhibitor therapy is discontinued.
睫毛增粗是一种罕见的药物相关后遗症，发生于表皮生长因子受体 (EGFR) 抑制剂治疗期间。这些药物引起的睫毛延长主要发生在患有结直肠癌或肺癌的肿瘤患者中。它最常与西妥昔单抗和厄洛替尼相关；然而，也有在接受吉非替尼或帕尼单抗治疗的个体中描述过。我们描述了一名转移性直肠癌女性的西妥昔单抗相关睫毛增粗。我们回顾了 EGFR 抑制剂相关睫毛增粗的临床表现、不良反应和处理。长睫毛不是药物限制的不良反应，一些患者认为这种变化具有美容增强效果。用剪刀修剪睫毛通常可以改善局部症状。在 EGFR 抑制剂治疗停止后，睫毛通常会在不同时间恢复到原来的长度。
